Bowen disease, also called as squamous cell carcinoma in situ, is a rare type of skin disorder characterized by development of slow-growing, red/pink scaly patches on the skin. These scaly patches are mostly observed in those areas of the body which are exposed to sun such as hands, legs, and others. Bowen disease is a noninvasive form of intraepidermal squamous cell carcinoma, which occurs only inside the epidermal (outer) layer of the skin. Scaly patches or lesions associated with Bowen disease are usually not painful and are easily treatable. These lesions may be flat or slightly raised and are usually not associated with any symptoms, but sometimes these lesions can show symptoms such as itch, pus, bleeding, and others. Lesions tend to grow very slowly over months or years, and can develop into squamous cell skin cancer if untreated. There is no proven cause of Bowen disease yet, but risk factors such as sun exposure, human papillomavirus (HPV) infection, immunosuppressive drugs, and others increase the risk of Bowen disease incidence.
Market Dynamics
The increasing incidence of Bowen disease, rising research and development activities for the development of novel therapeutics for the treatment of Bowen disease are the major factors that are expected to drive growth of the global Bowen disease treatment market over the forecast period. Moreover, increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are expected to boost the global Bowen disease market.
For instance, according to an article published in the Dermatologic Surgery journal in November 2019, the annual age-standardized incidence rates of Bowen disease in Caucasian population in Northern Europe per 100,000 people was found to be increased from 8.1 in 2003 to 68.9 in 2013 and is expected to increase in near future.
Key features of the study:
- This report provides in-depth analysis of the global Bowen disease treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Bowen disease treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Galderma S.A., Sirnaomics, Inc., PEPLIN INC, Ponce Therapeutics, Intas Laboratories Pvt Ltd, Cadila, Pharmaceuticals Ltd., VHB Life Sciences Limited, Neon Laboratories Ltd, Teva Pharmaceutical Ltd, and Actavis Group
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Bowen disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Bowen disease treatment market
Detailed Segmentation:
- Global Bowen Disease Treatment Market, By Drug Type:
- Fluorouracil
- Imiquimod
- Others
- Global Bowen Disease Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Bowen Disease Treatment Market, By Region:
- North America
- By Drug Type
- Fluorouracil
- Imiquimod
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Drug Type
- Fluorouracil
- Imiquimod
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Type
- Fluorouracil
- Imiquimod
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Type
- Fluorouracil
- Imiquimod
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Type
- Fluorouracil
- Imiquimod
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Type
- Fluorouracil
- Imiquimod
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Galderma S.A.*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Sirnaomics, Inc.
- PEPLIN INC
- Ponce Therapeutics
- Intas Laboratories Pvt Ltd
- Cadila Pharmaceuticals Ltd.
- VHB Life Sciences Limited
- Neon Laboratories Ltd
- Teva Pharmaceutical Ltd
- Actavis Group
“*” marked represents similar segmentation in other categories in the respective section.
